We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · October 07, 2021

Selumetinib in Children With Recurrent Optic Pathway and Hypothalamic LGG Without NF1



Additional Info

A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study
Neuro-oncology 2021 Oct 01;23(10)1777-1788, J Fangusaro, A Onar-Thomas, TY Poussaint, S Wu, AH Ligon, N Lindeman, O Campagne, A Banerjee, S Gururangan, LB Kilburn, S Goldman, I Qaddoumi, P Baxter, G Vezina, C Bregman, Z Patay, JY Jones, CF Stewart, MJ Fisher, LA Doyle, M Smith, IJ Dunkel, M Fouladi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading